Results 211 to 220 of about 17,985,271 (268)
The FASEB Journal, Volume 40, Issue 18, 30 September 2026.Cardioprotective hormone relaxin‐2 showed relevant effects on rat skeletal muscle by altering proteins linked to muscle function, regeneration, differentiation, mitochondrial function, glucose metabolism, and structural integrity and organization. Specifically, relaxin‐2 reduced the expression of 95 proteins, increased 32, and elicited unique proteins ...
Xocas Vázquez‐Abuín +11 more
wiley +1 more source
The FASEB Journal, Volume 40, Issue 17, 15 September 2026.Annexin A4 (A4) inhibits adenylyl cyclase 5 and may protect the heart during chronic β‐adrenergic stress. After 7 days of isoprenaline, A4‐deficient mice showed greater cardiomyocyte hypertrophy, prolonged action potentials, reduced Ito, preserved ICaL with altered activation, increased NCX1, and enhanced acute cAMP responsiveness compared with wild ...
Florentina Pluteanu +4 more
wiley +1 more source
Nucleic Acids as Emerging Regulators of Calcium Phosphate Biomineralization
The FASEB Journal, Volume 40, Issue 17, 15 September 2026.Calcium phosphate biomineralization has traditionally been considered a protein‐regulated process. This review highlights the emerging role of nucleic acids, which interact with mineral phases through adsorption, coprecipitation, and templating, thereby influencing crystal nucleation and growth.
Fanny Duhalde +2 more
wiley +1 more source
How to Evaluate the Efficacy of the Phosphodiesterase Type 5 Inhibitors
The Journal of Sexual Medicine, 2012 Several methods have been so far proposed to compare the effectiveness of the three available phosphodiesterase type 5 inhibitors (PDE5Is).Two urologists (E.C. and G.B.B.), together with the Controversy's Editor (E.A.J.), with expertise in the area of medical treatment of erectile dysfunction (ED) present the various perspectives on the evaluation of ...
JANNINI, EMMANUELE ANGELO FRANCESCO +3 more
openaire +7 more sources
New Avenues for Phosphodiesterase Inhibitors in Asthma
Journal of Experimental Pharmacology, 2021 Maria Gabriella Matera,1 Josuel Ora,2 Francesco Cavalli,2 Paola Rogliani,2,3 Mario Cazzola3 1Department of Experimental Medicine, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Respiratory Diseases Unit, “Tor Vergata&rdquo ...
Francesco Cavalli +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Phosphodiesterase Type 5 Inhibitors: The Day After
European Urology, 2007Review the literature on phosphodiesterase type 5 inhibitors (PDE5-Is), addressing critical issues in their current and future use, assessing unanswered questions, and identifying research needs.A MEDLINE search was conducted on PDE5-Is, with emphasis on clinical trials and experience, for interpretation and analysis of their present and future role ...
Konstantinos, Hatzimouratidis +1 more
openaire +2 more sources
Phosphodiesterase type 5 inhibitors for erectile dysfunction
BJU International, 2005This is our first presentation of Great Drug Classes, and we start with a description of phosphodiesterase type 5 inhibitors and their use in erectile dysfunction. This is an in‐depth review of this class of drugs, offering the reader a description of how they work, in which conditions they may be particularly beneficial, and a ...
Culley C, Carson, Tom F, Lue
openaire +2 more sources
Phosphodiesterase type 5 inhibitors and kidney disease
International Urology and Nephrology, 2015Chronic kidney disease (CKD) represents a worldwide health problem. Traditionally, the nephroprotective treatment for CKD aims to slow progression to end-stage renal disease and includes dietary protein restriction, correction of metabolic acidosis, and renin-angiotensin system blockers.
Baris, Afsar +6 more
openaire +2 more sources
Phosphodiesterase Type 5 Inhibitors: Unmet Needs
Current Pharmaceutical Design, 2009Erectile dysfunction (ED) has been revolutionized during the last two decades, as several treatment options are available today. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first choice treatment option for ED by most physicians and patients due to their high efficacy rates and favourable safety ...
K, Hatzimouratidis, D G, Hatzichristou
openaire +2 more sources
Phosphodiesterase Type 5 (PDE5) Inhibitors
2003Publisher Summary In recent years, the field of Phosphodiesterase Type 5 (PDE5) inhibitors has reached a state of maturity. Standard issues in medicinal chemistry, such as potency, selectivity, physico-chemical properties and oral bioavailability, have been successfully addressed with the known PDE5 inhibitors.
Helmut, Haning +2 more
openaire +2 more sources